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Abstract 
We assessed the suitability of 4beta-hydroxycholesterol (4bOH-C) as endogenous CYP3A 
phenotyping metric.  
4bOH-C and its ratio over cholesterol (4bOH-C/C) were determined in five cocktail 
phenotyping studies, with and without co-medication with a potential CYP3A inhibitor. These 
parameters were compared to established midazolam-based CYP3A metrics: i.v. (M-Cl) and 
apparent oral clearance (M-Cl/F) reflecting hepatic and overall activity, respectively. 
In a common evaluation of periods without co-medication, 4bOH-C and 4bOH-C/C correlated 
slightly positively to midazolam metrics: M-Cl (r=0.239 and 0.348), M-Cl/F (r=0.267 and 
0.353); p(one-sided)<0.05. Co-medication with lopinavir/ritonavir, causing a strong decrease 
in midazolam metrics, showed a mild decrease of cholesterol metrics. However, intake of 
propiverine gave opposite results for midazolam and cholesterol based metrics. 
The information currently available does not justify the use of 4bOH-C for estimation of basal 
CYP3A activity. Further studies addressing temporal variation of local CYP3A activity are 
needed to assess its role as biomarker during CYP3A inhibition. 
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Introduction 
Phenotyping for drug metabolizing enzymes (DME) or transporters enables the identification 
of potential factors affecting drug metabolism and disposition including drug-drug 
interactions(1). Phenotyping for CYP3A seems to be of special importance because about half 
the currently prescribed drugs are metabolized with participation of enzymes belonging to this 
family, particularly CYP3A4. However, selection of a proper CYP3A phenotyping substrate 
and metric is still a matter of discussion, although to date numerous CYP3A test substrates 
have been proposed, including midazolam, erythromycin, alprazolam, alfentanil, nifedipine, 
dapsone, omeprazole, dextromethorphan, and others.(2) At the same time identification of an 
appropriate endogenous CYP3A substrate and corresponding metrics would be a promising 
alternative allowing for simplification and maybe a broader application of the phenotyping 
approach. The oxidation of the endogenous compound cortisol to form 6beta-hydroxycortisol 
has been shown to be a CYP3A dependent pathway in humans. Consequently urinary 
excretion of 6beta-hydroxycortisol and its ratio to 17-hydroxycorticosteroids in 24 h urine 
sampling have been proposed as suitable phenotyping markers for the assessment of CYP3A 
activity.(3, 4) However, while this may be used to monitor CYP3A induction, the sensitivity 
of the respective metrics to detect small changes in the enzyme activity is low because of 
pronounced background variation(3). Recently Bodin at al. provided evidence for the role of 
CYP3A4 in in vitro hydroxylation of cholesterol to 4beta-hydroxycholesterol (4bOH-C), 
which was identified as one of the major oxysterols in man.(5) Following the observation that 
patients treated with antiepileptics like carbamazepine, phenytoin, or phenobarbital, which are 
strong inducers of several cytochrome P450 enzymes, had up to 20-fold higher plasma 
concentrations of this metabolite as compared to patients treated with antiepileptics not 
causing induction, the authors incubated cholesterol with recombinant human CYP3A4, 
CYP1A2, CYP2C9 and CYP2B6. Accordingly, only for CYP3A4, measurable formation of 
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4bOH-C has been identified, thus proving the key role of the enzyme for conversion of 
cholesterol to 4bOH-C.(5) Moreover, treatment with other known inductors of CYP3A like 
ursodeoxycholic acid, rifampicin or efavirenz was also shown to be related to increased 
plasma concentrations of 4bOH-C in patients.(5-8) Diczfalusy et al. demonstrated that 4bOH-
C plasma concentration was correlated to the number of active CYP3A5*1 alleles, in three 
different ethnic populations of healthy Swedes, Tanzanians and Koreans.(9) CYP3A5 is 
closely related to CYP3A4 and shows almost the same substrate spectrum, but its expression, 
in contrast to the ubiquitous CYP3A4, is limited to the carriers of at last one CYP3A5*1 allele 
(CYP3A5 expressers) and subject to a pronounced inter-individual and interracial variability. 
(10) Moreover, the authors observed a good correlation between 4bOH-C and the metabolic 
ratio of quinine/3-hydroxyquinine in plasma, which is a parameter proposed for CYP3A 
phenotyping.(9, 11) Accordingly, 4bOH-C has been suggested as potential endogenous 
biomarker of CYP3A activity.(9, 12).  
However, the available data on CYP3A phenotyping by 4bOH-C is quite limited and the 
metric has not been fully validated. Thus, the aim of our assessment is to expand the existing 
evidence base and provide clarification with respect to suitability of plasma concentrations of 
4bOH-C as a metric for CYP3A activity in humans.  
 
Results 
Data from 52 healthy, male subjects, and 27 HIV-positive male and female patients 
participating in one of five clinical cocktail phenotyping studies (termed A – E) were 
considered for this evaluation, however, two of the healthy volunteers participated in two 
studies each (for study designs and populations see also Method section and Table 1). Table 2 
shows means and standard deviations of 4bOH-C (given in ng/mL, which is the unit used in 
previously published data) and the metabolic ratio (molar) of 4bOH-C over cholesterol 
(4bOH-C/C) as well as those of CYP3A phenotyping parameters based on midazolam, i.e. 
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midazolam i.v. clearance (M-Cl) and apparent oral clearance (M-Cl/F), sorted by study and, 
for interaction studies B – E, by Reference and Test period. Tables 3 and 4 display the results 
of a correlation analysis between midazolam phenotyping parameters and, respectively, 
4bOH-C concentrations and 4bOH-C/C ratios. Taking into account the data of all healthy 
volunteers estimated across all studies for periods without co-administration of a potential 
CYP3A inhibitor, both cholesterol metrics were statistically significantly (p<0.05, one sided), 
however, weakly correlated to midazolam metrics reflecting hepatic (M-Cl) and total CYP3A 
activity (M-Cl/F). The correlation to M-Cl/F was somewhat stronger (M-Cl/F: r=0.27 and 
r=0.35 vs. M-Cl: r=0.24 and r=0.35, respectively, for 4bOH-C and 4bOH-C/C). At the same 
time, the 4bOH-C/C ratio performed slightly better than the 4bOH-C concentration alone (see 
Figure 1). For individual studies, as well as Test and Reference periods within one study, the 
coefficient of correlation r was occasionally in the opposite of the expected direction, and 
failed to reach statistical significance in most cases. (Tables 3 and 4).  
The effect of co-medication on CYP3A activity has been evaluated in interaction studies B – 
E. In studies C and D, no statistically significant changes with respect to both cholesterol 
metrics were observed upon administration of the tested drug in the Test period (see Table 3 
and 4, ratios Test/Reference), which was in concordance with the assessment of CYP3A 
activity based on midazolam metrics, also not showing any relevant interaction potential of 
the co-medication in those studies (data not shown). In contrast, in study B, chronic co-
administration of propiverine resulted in mild but statistically significant increase of both 
cholesterol parameters (see Table 3 and 4), but this was not supported by the midazolam 
metrics indicating a change in the opposite direction: the mean reductions (90%CI) of M-Cl 
and M-Cl/F, respectively, were 0.91-fold (0.88-fold - 0.94-fold) and 0.68-fold (0.63-fold - 
0.73-fold). In study E, chronic co-administration of a drug regimen containing ritonavir 
boosted lopinavir resulted in a rather small reduction of 4bOH-C and 4bOH-C/C (see Table 3 
and 4) whereas at the same time, pronounced reductions of M-Cl to the 0.24-fold (90%CI, 
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0.20-fold – 0.29-fold) and M-Cl/F to the 0.18-fold (90%CI, 0.15-fold – 0.23-fold) were 
observed. Figure 2 shows the mean changes in midazolam and cholesterol phenotyping 
metrics upon co-administration of both regimens, propiverine and ritonavir boosted lopinavir. 
Taking into account genotyping results, 49 subjects (69%) were homozygote carriers of 
CYP3A5*3, 16 subjects (23%) were heterozygote for this allele, and six subjects (8%), four of 
whom were of African origin, had the wild type genotype (CYP3A5*1/*1). The mean 
concentration of 4bOH-C and the mean 4bOH-C/C ratio increased with the number of the 
active CYP3A5*1 alleles, however this did not reach statistical significance (data not shown). 
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Discussion  
In the present evaluation, we studied the suitability of cholesterol based metrics, i.e. 4bOH-C 
and the 4bOH-C/C ratio in plasma as endogenous biomarkers of CYP3A activity and 
observed that only a small part of the variation in midazolam and cholesterol based metrics, 
respectively, shares the same source, and that cholesterol based metrics may reflect decreased 
CYP3A activity by co-administration of CYP3A inhibitor only if these have a strong effect. 
Despite the crucial role of CYP3A in drug metabolism, a reliable estimation of its actual 
activity is still challenging and a perfect phenotyping metric has not been identified yet. Using 
an endogenous substrate would obviously be the simplest and safest phenotyping method. For 
that reason, we focused on the usefulness of 4bOH-C, and the related parameter, the 4bOH-
C/C ratio, which may eliminate potential bias due to variations in plasma cholesterol, and 
compared these to established midazolam based CYP3A metrics (13). In fact, in the common 
evaluation of all healthy volunteers, both cholesterol metrics were statistically significantly 
correlated to i.v. clearance and, even more, apparent oral clearance of midazolam. However, 
this correlation was weak, and not consistently reflected in individual studies. Although the 
4bOH-C/C ratio seems to perform slightly better than 4bOH-C alone, the difference was 
minor, thus confirming earlier assumptions that 4bOH-C is not considerably influenced by 
cholesterol concentrations.(7, 9)  
One of the aims of our evaluation was to study the appropriateness of cholesterol based 
metrics to reflect possible changes in CYP3A activity by drug-drug interactions. In two 
interaction studies (C and D), lack of an effect on CYP3A was concordantly reflected by both 
midazolam and cholesterol based metrics. However, in the propiverine interaction study 
(study B), a small significant increase of 4bOH-C and the 4bOH-C/C ratio, suggesting 
induction of CYP3A, was in contrast to changes in midazolam metrics indicating inhibition of 
CYP3A.(14) Finally, in the ritonavir boosted lopinavir interaction study, cholesterol based 
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metrics reflect a moderated CYP3A inhibition, whereas midazolam based metrics indicate a 
strong inhibition of CYP3A activity. Noteworthy, these results are well in agreement with 
those of Josephson et al., who found a minor mean decrease of 4bOH-C of 11% following 
four weeks of therapy with ritonavir boosted lopinavir, both dosed like in our study, whereas 
a combination of atazanavir and ritonavir resulted in a higher and statistically significant 
reduction of 18% in this parameter.(6)  
 
Both the weak correlation between cholesterol and midazolam based CYP3A metrics and the 
in part contradictory results in the interaction studies clearly show that cholesterol and 
midazolam metrics do not measure exactly the same thing. Indeed, the problem of discordant 
results of independent CYP3A metrics has been addressed previously. An early example of a 
discordance is a lacking correlation between erythromycin breath test and midazolam 
clearance, both established and widely used CYP3A metrics.(15) Masica et al., who compared 
alprazolam, triazolam, and midazolam clearance as CYP3A metrics, concluded that no 
accurate prediction of pharmacokinetics of any other CYP3A substrate by CYP3A 
phenotyping would be possible.(16) Moreover, as different CYP3A substrates may vary not 
only in their biopharmaceutic properties (solubility and permeability), but also with respect to 
their properties as substrates to various transporters, the general usefulness of CYP3A 
phenotyping has been challenged.(17) However, Kharasch et al. demonstrated an almost 
identical magnitude of induction and inhibition of CYP3A activity, as a result of, respectively, 
rifampicin and troleandomycin administration by means of midazolam and alfentanil based 
metrics.(18) In our data, we cannot confirm that midazolam and 4bOH-C reflect CYP3A 
inhibition in the same way. However, we suggest that identification and quantification of 
covariates beyond CYP3A activity which determine the results of CYP3A phenotyping may 
overcome these current limitations of individual CYP3A metrics including those based on 
4bOH-C. 
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It may well be that processes beyond CYP3A activity involved in 4bOH-C formation, such as 
participation of other enzymes not yet tested, or in 4bOH-C elimination and/or transport are 
the reason for these discrepancies. Bodin at al., who showed that CYP3A4, but not CYP1A2, 
CYP2C9 and CYP2B6, is involved in formation of 4bOH-C in vitro, indeed did not test 
further enzymes.(5).  
 
However, a closer look suggests that the data do not necessarily exclude that both procedures 
reflect primarily CYP3A activity despite the discrepancies. Midazolam has a short elimination 
half-life of approximately 1.8 hours (19), while that reported for 4bOH-C is between around 
60 hours and 17 days. (12, 20) Thus, midazolam-based metrics reflect actual hepatic (Cl) or 
hepatic and intestinal (Cl/F) CYP3A activity, while 4bOH-C would represent a weighted 
average of CYP3A activity over a period of several days, and it is unclear to which extent gut 
wall CYP3A may contribute to cholesterol hydroxylation during intestinal absorption. Short-
term fluctuations in CYP3A activity could therefore be another reason for the observed 
discrepancies. There is some evidence that CYP3A activity has circadian variation.(21, 22) 
Furthermore, the degree of a competitive inhibition of CYP3A depends on actual local 
concentration, and there are very pronounced and rapid changes in gut wall and hepatic 
concentrations of a drug administered to assess its interaction with CYP3A in vivo. Oral 
midazolam in the studies reported here has been administered together with the respective test 
drugs, thus maximal concentrations of the interacting drugs were present at the enzyme at this 
time. Therefore, midazolam based metrics would be expected to capture maximal inhibition 
while cholesterol based metrics would be expected to reflect average inhibition. Ritonavir is 
reported as being the most potent CYP3A inhibitor and the extent of CYP3A inhibition 
quantified by means of midazolam phenotyping is clearly in concordance with the recently 
published data by Kharasch et al., who determined profound CYP3A inhibition upon 
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treatment with ritonavir using alfentanil, another CYP3A substrate with a short elimination 
half-life(23, 24). In addition, ritonavir is also an inducer of CYP3A.(6) Thus, assuming that 
both cholesterol and midazolam based metrics would depend virtually exclusively on CYP3A 
activity, an increase of overall CYP3A expression during ritonavir administration with a 
pronounced inhibition of CYP3A primarily shortly after administration which fades between 
administrations of individual ritonavir doses would be plausible and also compatible with all 
results. A similar explanation may hold true for the results obtained with propiverine, if this 
drug also causes some CYP3A induction. However, whereas induction of hepatic cytochrome 
P450 enzymes was observed following chronic administration of high doses of propiverine in 
rats(25), no respective data in man is available.  
 
The complexity of relationships between CYP3A activity and 4bOH-C concentrations is also 
reflected by data from Wide et al. (26), who found some inconsistency with respect to the 
time course of the increase in the cholesterol parameter and induction of the enzyme. Whereas 
CYP3A induction due to carbamazepine intake was definitely complete at the end of a two 
weeks period (as based on plasma concentrations of carbamazepine and its metabolite), 
4bOH-C continued to increase till eight weeks after therapy onset suggesting that CYP3A 
activity is not the only factor regulating the concentration of this endogenous biomarker.(26) 
Similarly in studies B and E, following the administration of propiverine and 
ritonavir/lopinavir for, respectively, one or two weeks a new steady state of 4bOH-C might 
not have been reached considering its very long elimination half-life. 
 
Beyond considering temporal variations in CYP3A activity, it is tempting to speculate on the 
site of cholesterol hydroxylation and the effective concentrations of cholesterol at the binding 
site of the enzyme. As cholesterol is present in huge concentrations in plasma, only a tiny 
fraction may reach the enzyme; otherwise, cholesterol would compete for any other substrate 
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and probably block CYP3A metabolism because substrate saturation was obtained above 100 
µM (5). 
 
A final aspect which may contribute to the discordant results for midazolam and cholesterol 
phenotyping is the differing substrate specificity between CYP3A4 and CYP3A5.(27) 
Although not confirmed in our evaluation, CYP3A5 polymorphism has been shown to 
significantly affect the cholesterol biomarker, whereas it has no influence on midazolam 
phenotyping.(9, 28) 
 
In summary, the current understanding of CYP3A and cholesterol 4-hydroxylation is not 
sufficient to establish 4bOH-C concentrations as endogenous CYP3A biomarker. Empirical 
data available suggest that cholesterol-based phenotyping metrics may be useful to assess 
CYP3A activity changes by strong CYP3A inducers and inhibitors. The current information 
does, however, not justify the use of 4bOH-C for estimation of basal CYP3A activity or to 
assess small changes in CYP3A activity. Further studies are needed to assess the 
appropriateness of individual CYP3A markers when taking short-term fluctuations of CYP3A 
activity and other covariates such as transporter activities into account.  
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Methods 
Cholesterol based metrics 4bOH-C and its ratio to cholesterol were evaluated in five clinical 
cocktail phenotyping studies (termed A – E), in which assessment of hepatic and overall 
(hepatic and intestinal) CYP3A activity has been previously studied using midazolam based 
metrics, respectively, i.v. clearance (M-Cl) and apparent oral clearance (M-Cl/F). Four of 
these studies (A - D) were performed in healthy, male, Caucasian volunteers and one study 
(E) in HIV positive male and female patients (five of them of African origin). Midazolam 
metrics were obtained upon low-dosed, semi-simultaneous oral (2 mg in studies A – D and 
1.5 mg in study E) and i.v. (1 mg) administration of the drug (Dormicum, Hoffmann-La 
Roche AG, Germany) given as part of the phenotyping cocktail. In study A, oral midazolam 
was given 1.5 hours after administration of the other cocktail components including i.v. 
midazolam. In studies B - E, i.v. midazolam was given four hours following the cocktail 
administration including oral midazolam.(14, 28-30). For the cocktail administrations, the 
subjects were under standardized fasting conditions. Whereas in study A the phenotyping 
cocktail was given only once (pilot cocktail study), studies B – E consisted of two periods 
(Test and Reference) with a co-administration of a potential CYP3A inhibitor (studies B - D) 
and a strong one (E) in Test period, respectively (see Table 1). In studies C and D, the identity 
of the investigational products, both not licensed, tested in one period with respect to the 
effect on CYP activity, is confidential. Data obtained in studies B and E have been published 
previously.(14, 29) All studies were approved by the ethics committee of the Medical Faculty 
of the University of Cologne, Germany, and were performed in accordance with the 
Declaration of Helsinki, and corresponding European and International guidelines. All 
participants gave their written informed consent. Study designs, demographics and baseline 
characteristics of the participants are displayed in Table 1.  
Midazolam was quantified by LC-MS/MS as described.(14, 29) Midazolam i.v. clearance and 
apparent oral clearance were calculated by compartmental population pharmacokinetic 
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analysis using NONMEM software (V version 1.1, NONMEM Project Group, University of 
California at San Francisco, 1998).(28)  
Concentrations of 4bOH-C and cholesterol to calculate the metabolic ratio of 4bOH-C over 
cholesterol (C/C) were quantified in plasma samples derived from blood collections 
performed just before i.v. administration of midazolam in study A and before oral 
administration of midazolam (together with other oral cocktail compounds) in studies B – E. 
The respective plasma samples were stored frozen at below -65 °C until analysis. Cholesterol 
in plasma was analyzed by gas chromatography-flame ionization detection using 5-
cholestane as internal standard.(31) Cholesterol concentration were within the clinical 
reference range in all studies and respective periods, Test and Reference.  
The concentration of the oxysterol 4bOH-C (as trimethylsilyl-derivative) was determined by 
an highly sensitive and specific isotope dilution methodology (gas chromatography-mass 
spectrometry) using [26.26.26.27.27.27-2H6] 4beta-hydroxycholesterol as internal 
standard.(5) Authentic 4beta-hydroxycholesterol was delivered by Steraloids, Inc. (Newport 
RI, USA) and deuterium labelled 4beta-hydroxycholesterol was synthesized as published 
previously.(32) The respective inter and intra-day precision were 2.1% and 2.7% and inter 
and intra-day accuracy were 2.9% and 3.3%. The low limit of quantification was 3.0 ng/mL 
and the linear range was 0.3 – 300 ng/mL. Long-term and freeze-thaw stability was proven.  
4bOH-C and 4bOH-C/C were compared to the midazolam metrics by correlation analysis 
(separately for all studies and periods and jointly for the periods without co-medication in the 
studies with healthy volunteers A - D). To this end Spearman’s rank correlation coefficient 
was used, and one-sided p-values were calculated since the anticipated direction of 
relationship, if any, was obvious. Because two healthy volunteers taking part in study B were 
later recruited for study C or D, respectively, their data derived from study B only were used 
for the common evaluation of periods without co-medication.  
Furthermore, for studies B – E, the interactions between co-medications and cholesterol 
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phenotyping metrics were evaluated as a bioequivalence problem.(33) For each interaction 
study, point estimates for the true ratios of respective parameters in the periods without 
(Reference) and with co-medications (Test), the corresponding 90% confidence intervals (CI) 
and intra-subject coefficients of variations (CV) were calculated. An interaction was assumed 
to be absent when both the point estimate and the 90% CI were entirely within the 
bioequivalence boundaries of 80–125% of the Reference values. Genotyping for 
determination of the most frequent single nucleotide polymorphism CYP3A5*3 has been 
described previously.(28) 
All calculations were done by SPSS (version 14.0, SPSS Inc., Chicago, IL, USA.) and 
WinNonlinTM, Version 2.1 (Pharsight Corp., Palo Alto, CA, USA.) 
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Figure legends 
 
Figure 1 
Correlation between 4bOH-C (left) and 4bOH-C/C (right) in plasma and i.v. clearance of 
midazolam; pooled data from 50 healthy volunteers (studies A - D) in the period without co-
medication (Reference); Spearman’s rank correlation coefficient = 0.239 (p = 0.048) and 
0.348 (p = 0.007), respectively, for 4bOH-C and 4bOH-C/C; 4bOH-C, 4beta-
hydroxycholesterol in plasma; 4bOH-C/C, molar ratio of 4beta-hydroxycholesterol over 
cholesterol in plasma;  
 
Figure 2 
Effect of ritonavir boosted lopinavir (left) and propiverine (right) on cholesterol (open 
symbols) and midazolam (closed symbols) CYP3A metrics; whiskers represent 90% 
confidence intervals; 4bOH-C, 4beta-hydroxycholesterol in plasma; 4bOH-C/C, molar ratio 
of 4beta-hydroxycholesterol over cholesterol in plasma; M-Cl, i.v. clearance of midazolam; 
M-Cl/F, apparent oral clearance of midazolam 
  
Table 1 Design of studies A – E and the respective demographics of the study populations 
 
Study Design Number of subjects 
available for the 
evaluation 
Age [years] BMI [kg/m2] 
     
A single period pilot cocktail study;  
 
 
n=8a 
healthy male 
Caucasian 
volunteers 
29 (25 - 36) 24.0 (21.2 – 26.4 ) 
B open, randomized, cross-over study (Test and 
Reference period) with chronic (one week) 
co-administration of propiverine 15 mg b.i.d. 
(Test) or placebo (Reference);  
cocktail administration: together with the 
morning dose of propiverine (Mictonorm®, 
APOGEPHA Arzneimittel GmbH, Germany) 
or placebo on day 7 
 
n=16 
healthy male  
Caucasian 
volunteers 
29 (23 - 42) 23.5 (21.5 – 26.6) 
C open, randomized, cross-over study (Test and 
Reference period) with co-administration of 
an investigational drug (Test) or placebo 
(Reference) given as single dose on two 
consecutive days;  
cocktail administration: two hours after 
administration of the investigational drug or 
placebo on day 2 
 
n=12 (11)b 
healthy male 
Caucasian 
volunteers  
38 (24 - 49) 24.5 (20.0 – 29.3) 
D double-blind, randomized, cross-over study 
(Test and Reference period) with chronic (one 
week) co-administration of an investigational 
drug given once a day (Test) or placebo 
(Reference);  
cocktail administration: together with 
administration of the investigational drug or 
placebo on day 7 
 
 
n=16 (15)b 
healthy male 
Caucasian 
volunteers  
 
29 (21 - 43) 24.1 (20.4 – 27.8) 
E prospective, two periods, open, fixed 
sequence study prior to (Reference period) 
and with chronic, i.e. at least 14 days co-
administration of ritonavir (100mg) boosted 
lopinavir (400mg) (Kaletra, Abbott, 
Wiesbaden, Germany) b.i.d. with zidovudine 
and lamivudine, respectively, 300mg and 
150mg, given b.i.d. (Test period);  
cocktail administration: together with 
antiretroviral treatment 
n=27c 
HIV positive male 
and female 
Caucasian  and 
African origin 
(n=6) patients 
39 (25 - 60) 23.6 (16.4 – 36.7) 
BMI, body mass index; age and BMI are given as mean and (range);  
aTen subjects participated in this study, however data from eight subjects only were available for the present 
evaluation. bOne subject from this study already participated in study B. c28 subjects participated in this study, 
however, data from 27 subjects only were available for the present evaluation. 
 
Table 2 Mean values and (standard deviations) of both cholesterol based metrics 4bOH-C and 
4bOH-C/C and midazolam metrics in all studies. For interaction studies B – D, the results are 
given separately for Reference and Test (=with co-medication) period 
 
Study Cholesterol phenotyping parameters Midazolam phenotyping parameters 
 4bOH-C 
[ng/mL] 
4bOH-C/C x104 
[-] 
M Cl 
[L/h] 
M Cl/F 
[L/h] 
A - 20.45 (5.86) 0.12 (0.04) 22.43 (3.56) 37.23 (7.51) 
B Reference 23.87 (4.99) 0.14 (0.03) 26.97 (5.32) 81.99 (18.44) 
 Test 28.70 (7.29) 0.18 (0.03) 24.45 (5.36) 55.86 (15.05) 
C Reference 22.81 (9.13) 0.13 (0.05) 17.02 (4.11) 55.94 (23.58) 
 Test 23.74 (8.08) 0.13 (0.04) 17.44 (3.85) 56.85 (26.70) 
D Reference 18.75 (5.28) 0.11 (0.03) 20.97 (5.74) 71.27 (27.11) 
 Test 18.10 (5.47) 0.10 (0.02) 20.58 (5.28) 65.60 (28.24) 
E Reference 42.72 (33.70) 0.28 (0.20) 25.17 (6.42) 44.42 (21.24) 
 Test 31.16 (23.11) 0.19 (0.12) 6.51 (2.91) 8.49 (4.04) 
 
4bOH-C, 4beta-hydroxycholesterol in plasma given in ng/mL, 4bOH-C/C,molar ratio of 4beta-
hydroxycholesterol over cholesterol in plasma; Ref, Reference period; Test, Test period with co-medication of 
potential inhibitor; M-Cl, i.v. clearance of midazolam; M-Cl/F, apparent oral clearance of midazolam 
 
Table 3 Correlation of 4beta-hydroxycholesterol concentrations in plasma to midazolam 
based CYP3A metrics 
 
Comparison 
 
all healthy 
vol. (Ref) 
Study A 
 
Study B 
(Ref) 
Study B 
(Test) 
Study C 
(Ref) 
Study C 
(Test) 
Study D 
(Ref) 
Study D 
(Test) 
Study E 
(Ref) 
Study E 
(Test) 
n 50a 8 16 16 12 12 16 16 27 27 
rs to M-Cl 
p single-sided 
 
0.239 
0.048 
-0.071 
0.433 
 
0.235 
0.190 
 
-0.168 
0.267 
 
-0.098 
0.381 
 
0.070 
0.415 
 
0.559 
0.012 
 
0.216 
0.210 
 
0.079 
0.347 
 
-0.131 
0.258 
 
rs to M CI/F  
p single-sided 
 
0.267 
0.031 
 
0.048 
0.455 
 
0.082 
0.381 
 
-0.338 
0.100 
 
0.231 
0.235 
 
0.273 
0.196 
 
0.638 
0.004 
 
0.132 
0.313 
 
0.098 
0.313 
 
-0.143 
0.239 
 
Ratio Test/Reference 
for 4bOH-C 
(90% Cl) 
Intrasubject CV (%) 
n. a. 
 
n. a. 
 
1.190 
(1.083–1.308) 
15.2 
1.068 
(0.988–1.154)
10.5 
0.970 
(0.863-1.089) 
18.9 
0.730  
(0.529-1.008) 
27.0 
 
Ref, Reference period; Test, Test period with co-medication of potential inhibitor; M-Cl, i.v. clearance of 
midazolam; M-Cl/F, apparent oral clearance of midazolam; 4bOH-C, 4beta-hydroxycholesterol; CI, confidence 
interval; intrasubject CV, intrasubject coefficient of variation; rs, Spearman’s rank correlation coefficient; 
statistically significant (p<0.05, one-sided test) results are printed in bold.  
aOne subject from each study C and D previously participated in study B, so that, for these subjects, the data 
derived from study B only were used for the common evaluation of periods without co-medication in healthy 
volunteers 
 
 
 
 
Table 4 Correlation of 4beta-hydroxycholesterol/cholesterol concentration ratios in plasma to 
midazolam based CYP3A metrics 
 
Comparison 
 
all healthy 
vol. (Ref) 
Study A 
 
Study B 
(Ref) 
Study B 
(Test) 
Study C 
(Ref) 
Study C 
(Test) 
Study D 
(Ref) 
Study D 
(Test) 
Study E 
(Ref) 
Study E 
(Test) 
n 
 
50a 8 
 
16 16 12 12 16 16 
 
27 
 
27 
rs to M-Cl 
 p single-sided 
 
0.348 
0.007 
 
0.286 
0.246 
 
0.476 
0.031 
 
0.353 
0.090 
 
-0.189 
0.278 
 
0.147 
0.324 
 
0.506 
0.023 
 
0.297 
0.132 
 
0.219 
0.137 
 
-0.254 
0.101 
 
rs to M CI/F 
 p single-sided 
 
0.353 
0.006 
 
0.310 
0.228 
 
0.332 
0.104 
 
0.288 
0.139 
 
0.133 
0.340 
 
0.224 
0.242 
 
0.776 
0.000 
 
0.394 
0.065 
 
0.168 
0.200 
 
-0.255 
0.100 
 
Ratio Test/Reference 
for 4bOH-C/C 
 (90% Cl) 
intrasubject CV (%) 
 
n. a. 
 
n. a. 
 
1.279 
(1.162-1.409) 
15.5 
1.058 
(0.985-1.136) 
9.7 
0.994 
(0.912-1.084) 
13.9 
0.702 
(0.540-0.912) 
26.5 
 
Ref, Reference period; Test, Test period with co-medication of potential inhibitor; M-Cl, i.v. clearance of 
midazolam; M-Cl/F, apparent oral clearance of midazolam; 4bOH-C/C,molar ratio of 4beta-hydroxycholesterol 
over cholesterol; CI, confidence interval; intrasubject CV, intrasubject coefficient of variation; rs, Spearman’s 
rank correlation coefficient; statistically significant (p<0.05, one-sided test) results are printed in bold.  
aOne subject from each study C and D previously participated in study B, so that, for these subjects, the data 
derived from study B only were used for the common evaluation of periods without co-medication in healthy 
volunteers 
 
 


